Leveraging NKG2D Ligands in Immuno-Oncology

Leveraging NKG2D Ligands in Immuno-Oncology

Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened new avenues towards the development of novel assets to achieve durable immune control of cancer. Yet, the presence of tumor immune evasion mechanisms represents a challenge for the development of efficient trea...

Full description

Bibliographic Details
Main Authors:	Mercedes Beatriz Fuertes, Carolina Inés Domaica, Norberto Walter Zwirner
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Immunology
Subjects:	NK cells NKG2D MICA tumor immunity immuno-oncology
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.713158/full

Similar Items

Molecular bases for the regulation of NKG2D ligands in cancer
by: Leticia eHuergo-Zapico, et al.
Published: (2014-03-01)

Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications
by: Jimenez-Perez Miriam I, et al.
Published: (2012-02-01)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
by: Christine Koch, et al.
Published: (2017-11-01)

POTENTIAL USAGE OF NK CELLS AND NKG2D-POSITIVE LYMPHOCYTES AS TARGETS IN THERAPY OF CROHN’S DISEASE
by: E. A. Shulenina, et al.
Published: (2017-08-01)

INHIBITION OF THE NKG2D ACTIVATING RECEPTOR EXPRESSION ON CYTOTOXIC LYMPHOCYTES BY RECOMBINANT MICA PROTEIN
by: E. V. Abakushina, et al.
Published: (2017-01-01)

Human NKG2D-ligands: cell biology strategies to ensure immune recognition
by: Lola eFernández-Messina, et al.
Published: (2012-09-01)

Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia
by: Zhenhui Wu, et al.
Published: (2021-05-01)

NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells
by: Samantha Xing, et al.
Published: (2020-01-01)

NKG2D and Its Ligands: “One for All, All for One”
by: Alessandra Zingoni, et al.
Published: (2018-03-01)

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
by: Tobias Zöller, et al.
Published: (2018-03-01)

MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA
by: Younghoon Kim, et al.
Published: (2020-06-01)

Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application
by: Shijia ZHANG, et al.
Published: (2017-09-01)

Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
by: Richard Baugh, et al.
Published: (2020-12-01)

NKG2D Polymorphism in Melanoma Patients from Southeastern Spain
by: Lourdes Gimeno, et al.
Published: (2019-03-01)

The impact of Glycosyl-Phosphatidyl-Inositol anchored MICA alleles on novel NKG2D-based therapies
by: Mar eVales-Gomez
Published: (2015-04-01)

NKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications
by: Jagoda Siemaszko, et al.
Published: (2021-06-01)

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
by: Jennifer eWu, et al.
Published: (2015-03-01)

A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression
by: Trever T Greene, et al.
Published: (2016-11-01)

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
by: Valeria Cognigni, et al.
Published: (2021-04-01)

Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer
by: Chen J, et al.
Published: (2015-12-01)

Development and Characterization of Anti-CD20-NKG2D-Ligand Fusion Proteins
by: Harris, Patrice N
Published: (2011)

Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma
by: Steven T. Cox, et al.
Published: (2018-06-01)

Echinococcus multilocularis inoculation induces NK cell functional decrease through high expression of NKG2A in C57BL/6 mice
by: Abuduaini Abulizi, et al.
Published: (2019-09-01)

Corrigendum: Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma
by: Steven T. Cox, et al.
Published: (2020-02-01)

Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
by: Mariya Lazarova, et al.
Published: (2019-11-01)

Lights and Shadows in Immuno-Oncology Drug Development
by: Milana Bergamino Sirvén, et al.
Published: (2021-02-01)

NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
by: Alexandra Frazao, et al.
Published: (2019-03-01)

The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma
by: Philippe Merle
Published: (2021-01-01)

Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells
by: Haeryung Cho, et al.
Published: (2021-06-01)

Anti-NKG2D mAb: A New Treatment for Crohn’s Disease?
by: Kasper Vadstrup, et al.
Published: (2017-09-01)

Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response
by: Stipan eJonjic
Published: (2011-12-01)

Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity
by: Eric Alves, et al.
Published: (2021-08-01)

MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner
by: Changchun Du, et al.
Published: (2019-08-01)

Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK Cells
by: Peggy Riese, et al.
Published: (2020-06-01)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
by: Kirill Peskov, et al.
Published: (2019-04-01)

NKG2A/CD94 is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain
by: Gia-Gia T. Hò, et al.
Published: (2020-06-01)

NKG2D: A Master Regulator of Immune Cell Responsiveness
by: Felix M. Wensveen, et al.
Published: (2018-03-01)

Utilizing Humanized Mice to Study Human Specific Innate Immune Responses in Immuno-Oncology
by: Aryee, Ken-Edwin
Published: (2019)

Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment
by: Tristan Courau, et al.
Published: (2019-03-01)

The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
by: Talia Golan, et al.
Published: (2017-12-01)